Sigma Planning Corp Boosts Holdings in Becton, Dickinson and Company (BDX)

Sigma Planning Corp boosted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 5.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,213 shares of the medical instruments supplier’s stock after buying an additional 375 shares during the quarter. Sigma Planning Corp’s holdings in Becton, Dickinson and were worth $1,407,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of BDX. Waldron LP acquired a new position in Becton, Dickinson and during the 1st quarter worth $383,000. Dowling & Yahnke LLC lifted its holdings in Becton, Dickinson and by 1.2% during the 1st quarter. Dowling & Yahnke LLC now owns 7,726 shares of the medical instruments supplier’s stock worth $1,417,000 after buying an additional 95 shares in the last quarter. DUPONT CAPITAL MANAGEMENT Corp lifted its holdings in Becton, Dickinson and by 11.4% during the 1st quarter. DUPONT CAPITAL MANAGEMENT Corp now owns 50,676 shares of the medical instruments supplier’s stock worth $9,296,000 after buying an additional 5,186 shares in the last quarter. Alerus Financial NA lifted its holdings in Becton, Dickinson and by 3.9% during the 1st quarter. Alerus Financial NA now owns 19,386 shares of the medical instruments supplier’s stock worth $3,557,000 after buying an additional 722 shares in the last quarter. Finally, Wetherby Asset Management Inc. lifted its holdings in Becton, Dickinson and by 5.0% during the 1st quarter. Wetherby Asset Management Inc. now owns 5,898 shares of the medical instruments supplier’s stock worth $1,082,000 after buying an additional 283 shares in the last quarter. 87.43% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This story was first posted by Markets Daily and is owned by of Markets Daily. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.themarketsdaily.com/2017/09/13/sigma-planning-corp-boosts-holdings-in-becton-dickinson-and-company-bdx.html.

In related news, insider Gary M. Cohen sold 15,512 shares of the business’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $203.77, for a total value of $3,160,880.24. Following the transaction, the insider now owns 95,781 shares in the company, valued at $19,517,294.37. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of the business’s stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the completion of the transaction, the insider now owns 12,861 shares in the company, valued at approximately $2,538,890.01. The disclosure for this sale can be found here. In the last quarter, insiders have sold 75,904 shares of company stock worth $15,242,688. 1.40% of the stock is owned by company insiders.

Several research analysts have issued reports on the company. BidaskClub raised Becton, Dickinson and from a “hold” rating to a “buy” rating in a report on Monday, August 14th. Cowen and Company reaffirmed an “outperform” rating and set a $230.00 price objective (up previously from $200.00) on shares of Becton, Dickinson and in a report on Monday, July 10th. Barclays PLC reaffirmed an “equal weight” rating and set a $210.00 price objective (up previously from $205.00) on shares of Becton, Dickinson and in a report on Thursday, August 10th. Zacks Investment Research raised Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective on the stock in a report on Monday, July 17th. Finally, Raymond James Financial, Inc. raised Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and reduced their price objective for the stock from $210.00 to $180.00 in a report on Friday, June 30th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $196.93.

Becton, Dickinson and Company (BDX) opened at 202.20 on Wednesday. Becton, Dickinson and Company has a 1-year low of $161.29 and a 1-year high of $206.63. The firm has a market cap of $46.01 billion, a P/E ratio of 58.56 and a beta of 1.06. The stock has a 50 day moving average price of $200.08 and a 200-day moving average price of $191.02.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, topping analysts’ consensus estimates of $2.44 by $0.02. The company had revenue of $3.04 billion for the quarter, compared to analyst estimates of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. Becton, Dickinson and’s revenue was down 5.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.35 earnings per share. Equities research analysts forecast that Becton, Dickinson and Company will post $9.46 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be issued a dividend of $0.73 per share. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.44%. Becton, Dickinson and’s dividend payout ratio (DPR) is presently 83.43%.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply